Meloxicam

Meloxicam, the active ingredient in Meloxicam, is a Nonsteroidal anti-inflammatory drug (NSAID) presented as an oral tablet for oral use. It treats osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and acute pain in adults.

GNH USA supplies Meloxicam as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Meloxicam is an NSAID indicated for several inflammatory joint disorders and acute pain conditions.

Osteoarthritis: reduces joint pain and inflammation, improving mobility. Rheumatoid arthritis: alleviates synovial inflammation and joint swelling. Ankylosing spondylitis: diminishes spinal pain and stiffness. Acute pain: provides short‑term relief of moderate to severe pain.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Gastrointestinal discomfort or dyspepsia - Nausea or vomiting - Headache - Dizziness - Peripheral edema - Elevated blood pressure

Serious or Rare Side Effects: - Peptic ulcer perforation or gastrointestinal bleeding - Severe skin reactions such as Stevens‑Johnson syndrome - Acute renal impairment or failure - Cardiovascular thrombotic events (e.g., myocardial infarction, stroke)

Before prescribing meloxicam, clinicians should consider several safety factors.

Assess renal function: adjust use in patients with impaired kidney function. Monitor blood pressure: NSAIDs can raise systemic pressure. Avoid in known hypersensitivity: discontinue if allergic reactions occur. Use caution with anticoagulants: increased bleeding risk. Store at room temperature: keep in the original pack, protect from moisture.

Meloxicam can interact with a range of medicines, requiring careful management.

Major Interactions (Avoid): - Warfarin: heightened bleeding tendency. - Lithium: increased serum lithium concentrations. - Methotrexate: enhanced toxicity and reduced clearance.

Moderate Interactions (Monitor Closely): - ACE inhibitors: possible decline in renal function. - Diuretics: risk of electrolyte imbalance and dehydration. - SSRIs or SNRIs: potential for additive bleeding risk.